EA201001119A1 - Производные (гет)арил-п-хинона для лечения митохондриальных болезней - Google Patents
Производные (гет)арил-п-хинона для лечения митохондриальных болезнейInfo
- Publication number
- EA201001119A1 EA201001119A1 EA201001119A EA201001119A EA201001119A1 EA 201001119 A1 EA201001119 A1 EA 201001119A1 EA 201001119 A EA201001119 A EA 201001119A EA 201001119 A EA201001119 A EA 201001119A EA 201001119 A1 EA201001119 A1 EA 201001119A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- het
- aryl
- methods
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Раскрываются способы лечения или подавления митохондриальных болезней, таких как атаксия Фридрейха (FRDA), наследственная нейропатия зрительного нерва Лебера (LHON), митохондриальная миопатия, энцефалопатия, лактоцидоз, инсульт (MELAS), синдром Кернса-Сейра (KSS), а также соединения, пригодные в способах изобретения, такие как производные 2-(3-гидрокси-3-метилбутил)-6-(гет)арил-п-хинона или 2-(3-гидрокси-3-метилбутил)-3-(гет)арил-п-хинона. Также раскрываются энергетические биомаркеры, пригодные для оценивания метаболического состояния субъекта и эффективности лечения. Также раскрываются способы модулирования, нормализации или увеличения энергетических биомаркеров, а также соединения, пригодные для таких способов.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1038708P | 2008-01-08 | 2008-01-08 | |
US1040908P | 2008-01-08 | 2008-01-08 | |
PCT/US2009/030229 WO2009089224A1 (en) | 2008-01-08 | 2009-01-06 | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201001119A1 true EA201001119A1 (ru) | 2011-02-28 |
EA023618B1 EA023618B1 (ru) | 2016-06-30 |
Family
ID=40853439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001119A EA023618B1 (ru) | 2008-01-08 | 2009-01-06 | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
Country Status (6)
Country | Link |
---|---|
US (2) | US8952071B2 (ru) |
EP (1) | EP2237664A4 (ru) |
JP (3) | JP5649454B2 (ru) |
CA (1) | CA2708961C (ru) |
EA (1) | EA023618B1 (ru) |
WO (1) | WO2009089224A1 (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514461B2 (en) | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
DK1888059T3 (en) * | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
EP2220030B1 (en) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
WO2009089224A1 (en) * | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
EP2262519A4 (en) * | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE DEFICIENCIES WITH THERAPEUTIC AGENTS WITH REDOX ACTIVITY |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
PL2963006T3 (pl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie |
NO2424495T3 (ru) | 2009-04-28 | 2018-06-16 | ||
NO2470168T3 (ru) * | 2009-08-26 | 2018-06-30 | ||
KR102112087B1 (ko) | 2011-04-26 | 2020-05-18 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
WO2012148929A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Disorders implicating pufa oxidation |
KR102014524B1 (ko) | 2011-04-26 | 2019-08-26 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
EP2701695B1 (en) | 2011-04-26 | 2019-04-03 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
EP3943081A1 (en) | 2014-03-13 | 2022-01-26 | Retrotope, Inc. | Optic neuropathy treatment and reduction of steroid- induced oxidative stress with stabilized polyunsaturated substances |
SI3233786T1 (sl) | 2014-12-16 | 2022-08-31 | PTC Therapeutics, Inc., | Polimorfne in amorfne oblike (R)-2-hidroksi-2-metil-4-(2,4,5-trimetil- 3,6-dioksocikloheksa-1,4-dienil)butanamida |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
JP7132630B2 (ja) | 2016-11-17 | 2022-09-07 | レトロトップ、 インコーポレイテッド | 同位体修飾成分及びその治療上の使用 |
JP2022505257A (ja) | 2018-10-17 | 2022-01-14 | ピーティーシー セラピューティクス, インコーポレイテッド | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン |
JP2024525232A (ja) | 2021-07-08 | 2024-07-10 | ピーティーシー セラピューティクス、インコーポレイテッド | 2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを含む医薬組成物 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57183782A (en) | 1981-04-30 | 1982-11-12 | Sumitomo Chem Co Ltd | Preparation of coumarone compound |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US20020132845A1 (en) | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
WO2003015494A2 (en) | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
WO2003043570A2 (en) | 2001-11-15 | 2003-05-30 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
ATE328283T1 (de) | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
US7491312B2 (en) | 2002-10-30 | 2009-02-17 | Edison Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
US7514461B2 (en) | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
DK1888059T3 (en) | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
DK1933821T3 (da) | 2005-09-15 | 2020-10-26 | Ptc Therapeutics Inc | Halevarianter af redox-aktive terapeutika til behandling af mitokondriesygdomme og andre tilstande og modulation af energibiomarkører |
EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
WO2008002641A2 (en) | 2006-06-28 | 2008-01-03 | The Cleveland Clinic Foundation | Protein phosphatase inhibitors |
CA2674368A1 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
EP2220030B1 (en) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
US20100266591A1 (en) | 2008-01-07 | 2010-10-21 | Peter Bugelski | Method of treating erythropoietin hyporesponsive anemias |
WO2009089224A1 (en) | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE DEFICIENCIES WITH THERAPEUTIC AGENTS WITH REDOX ACTIVITY |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
CA2723621A1 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
EP2303309A2 (en) | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
WO2010014361A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
PL2963006T3 (pl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie |
NO2424495T3 (ru) | 2009-04-28 | 2018-06-16 | ||
CA2759984A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
CA2760357A1 (en) | 2009-04-28 | 2010-11-04 | Ampere Life Sciences, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
MX2011013558A (es) | 2009-06-25 | 2012-04-30 | Ampere Life Sciences Inc | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
NO2470168T3 (ru) | 2009-08-26 | 2018-06-30 | ||
WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
AU2011238525A1 (en) | 2010-04-06 | 2012-11-08 | Edison Pharmaceuticals, Inc. | Treatment of Ataxia Telangiectasia |
AU2011245384C1 (en) | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
EP2601168A4 (en) | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
CA2807507A1 (en) | 2010-08-06 | 2012-02-09 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with naphthoquinones |
US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
JP2016520621A (ja) | 2013-05-31 | 2016-07-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのカルボン酸誘導体 |
-
2009
- 2009-01-06 WO PCT/US2009/030229 patent/WO2009089224A1/en active Application Filing
- 2009-01-06 US US12/811,694 patent/US8952071B2/en not_active Expired - Fee Related
- 2009-01-06 JP JP2010542313A patent/JP5649454B2/ja not_active Expired - Fee Related
- 2009-01-06 EA EA201001119A patent/EA023618B1/ru not_active IP Right Cessation
- 2009-01-06 CA CA2708961A patent/CA2708961C/en not_active Expired - Fee Related
- 2009-01-06 EP EP09700856.9A patent/EP2237664A4/en not_active Withdrawn
-
2013
- 2013-12-26 JP JP2013268441A patent/JP2014058569A/ja not_active Withdrawn
-
2014
- 2014-12-30 US US14/586,516 patent/US9486435B2/en not_active Expired - Fee Related
-
2015
- 2015-12-03 JP JP2015236261A patent/JP2016034979A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2237664A4 (en) | 2013-05-22 |
EA023618B1 (ru) | 2016-06-30 |
EP2237664A1 (en) | 2010-10-13 |
CA2708961A1 (en) | 2009-07-16 |
JP5649454B2 (ja) | 2015-01-07 |
CA2708961C (en) | 2017-03-28 |
JP2016034979A (ja) | 2016-03-17 |
US20150297551A1 (en) | 2015-10-22 |
WO2009089224A1 (en) | 2009-07-16 |
US9486435B2 (en) | 2016-11-08 |
JP2014058569A (ja) | 2014-04-03 |
JP2011509298A (ja) | 2011-03-24 |
US20110046219A1 (en) | 2011-02-24 |
US8952071B2 (en) | 2015-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
EA200702622A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и других состояний и модуляции энергетических биомаркеров | |
EA200801623A1 (ru) | Варианты редокс-активных терапевтических средств для лечения митохондриальных заболеваний и других состояний и модуляции биомаркеров энергии, отличающиеся по боковой цепи | |
EA201000756A1 (ru) | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ | |
CY1123740T1 (el) | Παραλλαγες ακρων δραστικων οξειοδοαναγωγικων θεραπειων για αγωγη σε μιτοχονδριακες νοσους και αλλες καταστασεις και ρυθμιση των ενεργειακων βιοδεικτων | |
EA201300215A1 (ru) | Лечение митохондриальных болезней нафтохинонами | |
EP2601168A4 (en) | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K | |
CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
NI201100108A (es) | Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas. | |
BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
EA201892680A1 (ru) | Композиция для укрепления волос и способ укрепления волос | |
BRPI0915105A2 (pt) | composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer | |
CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
CR20120063A (es) | Heterociclos microbicidas | |
BRPI0922686A2 (pt) | associação de licopeno, polifenol e vitaminas para o cuidado das matérias queratínicas | |
UY34480A (es) | Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas. | |
DOP2011000319A (es) | Formulaciones liquidas de sales de 1-[2-(2,4- dimetilfenilsulfanil)-fenil]-piperazina | |
BRPI0815048B8 (pt) | derivados de fenóxi-pirrolidinas, seus usos e composições farmacêuticas | |
EA201400879A1 (ru) | Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp | |
RU2013129856A (ru) | Способ количественного определения доз дезинфицирующего уф-излучения при помощи индикаторов | |
BRPI0915428A2 (pt) | derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios | |
CY1108942T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-αρυλαμινης δια χρησιν εις την θεραπειαν συναισθηματικων διαταραχων, πονου, adhd και αγχους ακρατειας ουρων | |
CY1120654T1 (el) | Ενωσεις για χρηση στη θεραπευτικη αγωγη διαταραχων που βελτιωνονται μεσω αναστολης της hdac | |
UY33495A (es) | Derivados de bisaril (tio)morfolina como moduladores s1p |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in name of a patent proprietor in a eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |